BIOMAT Database Logo BIOMAT Database Logo

Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. 1986

J P O'Connell, and M G Kris, and R J Gralla, and S Groshen, and A Trust, and J J Fiore, and D P Kelsen, and R T Heelan, and R B Golbey

To determine the frequency and prognostic importance of pretreatment clinical characteristics in patients currently undergoing treatment for stage III non-small-cell lung cancer (NSCLC), data were collected on 378 patients receiving high-dose (120 mg/m2) cisplatin plus vinca alkaloid combination chemotherapy regimens since 1978. Variables analyzed included age, sex, weight loss, performance status, histologic subtype, presence of extrathoracic metastases, number of metastatic organ sites, presence of liver, bone, or brain involvement, prior radiation or surgery, and serum lactate dehydrogenase (LDH). The effect of a major response to chemotherapy on survival was also investigated. Using multivariable analyses, the following were found to be associated with outcome: initial performance status, with patients having a performance status of 80% to 100% having an increased major objective response rate and survival; bone metastases, which were adversely predictive of response rate and survival; elevated serum LDH and male sex, both of which were associated with shortened survival and remission duration; and the presence of two or more extrathoracic metastatic organ sites, which was associated with shorter survival. When major objective response with chemotherapy was included in a conditional multivariable analysis, it was strongly associated with longer median survival. Information from this analysis may be useful when comparing the response data of completed studies in similar patients, in designing future trials, and in the selection of cisplatin plus vinca alkaloid therapy for individual patients with advanced NSCLC.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D003625 Data Collection Systematic gathering of data for a particular purpose from various sources, including questionnaires, interviews, observation, existing records, and electronic devices. The process is usually preliminary to statistical analysis of the data. Data Collection Methods,Dual Data Collection,Collection Method, Data,Collection Methods, Data,Collection, Data,Collection, Dual Data,Data Collection Method,Method, Data Collection,Methods, Data Collection
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J P O'Connell, and M G Kris, and R J Gralla, and S Groshen, and A Trust, and J J Fiore, and D P Kelsen, and R T Heelan, and R B Golbey
Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy.
February 2003, Journal of cancer research and clinical oncology,
J P O'Connell, and M G Kris, and R J Gralla, and S Groshen, and A Trust, and J J Fiore, and D P Kelsen, and R T Heelan, and R B Golbey
[Prognostic factors affecting survival and response in patients with advanced non-small cell lung cancer treated with combination chemotherapy].
March 1990, Gan to kagaku ryoho. Cancer & chemotherapy,
J P O'Connell, and M G Kris, and R J Gralla, and S Groshen, and A Trust, and J J Fiore, and D P Kelsen, and R T Heelan, and R B Golbey
Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy.
January 2009, Oncology,
J P O'Connell, and M G Kris, and R J Gralla, and S Groshen, and A Trust, and J J Fiore, and D P Kelsen, and R T Heelan, and R B Golbey
A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy.
January 1992, Cancer chemotherapy and pharmacology,
J P O'Connell, and M G Kris, and R J Gralla, and S Groshen, and A Trust, and J J Fiore, and D P Kelsen, and R T Heelan, and R B Golbey
Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy.
January 2011, Lung cancer international,
J P O'Connell, and M G Kris, and R J Gralla, and S Groshen, and A Trust, and J J Fiore, and D P Kelsen, and R T Heelan, and R B Golbey
[Nimotuzumab in combination with chemotherapy in patients with advanced non-small cell lung cancer].
August 2011, Zhonghua zhong liu za zhi [Chinese journal of oncology],
J P O'Connell, and M G Kris, and R J Gralla, and S Groshen, and A Trust, and J J Fiore, and D P Kelsen, and R T Heelan, and R B Golbey
Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.
September 2023, Cancers,
J P O'Connell, and M G Kris, and R J Gralla, and S Groshen, and A Trust, and J J Fiore, and D P Kelsen, and R T Heelan, and R B Golbey
Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.
April 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
J P O'Connell, and M G Kris, and R J Gralla, and S Groshen, and A Trust, and J J Fiore, and D P Kelsen, and R T Heelan, and R B Golbey
Clinical impact of pretreatment prognostic nutritional index (PNI) in small cell lung cancer patients treated with platinum-based chemotherapy.
September 2018, The clinical respiratory journal,
J P O'Connell, and M G Kris, and R J Gralla, and S Groshen, and A Trust, and J J Fiore, and D P Kelsen, and R T Heelan, and R B Golbey
Combination chemotherapy of gemcitabine and vinorelbine in patients with advanced non-small cell lung cancer.
December 2004, Lung cancer (Amsterdam, Netherlands),
Copied contents to your clipboard!